We also demonstrate the negative regulatory role of IL-10 in C. jejuni induced autoimmunity and provide IL-4 and Siglec-1 blockade as potential therapeutic interventions against GBS. This evidence concerns the gene IL10 and Guillain-Barre syndrome.